Prescription drug expenditures rising - Too fast?;Les dépenses en médicaments d'ordonnance: Hors de contrôle?

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 10, 2005, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

CANADA; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; EDITORIAL; HUMAN; MEDICAL INFORMATION SYSTEM; PRESCRIPTION; SIDE EFFECT;

EID: 19744365439     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.050460     Document Type: Editorial

References (6)

1. Canadian Institute for Health Information. Drug expenditure in Canada 1985 to 2004. Ottawa: The Institute; 2005.
2. Eggertson E. Canadians spending more on drugs. CMAJ 2005;172(10):1279.
3. Morgan S. Canadian prescription drug costs surpass $18 billion. CMAJ 2005; 172(10):1323-4.
4. We need Romanow's National Drug Agency [editorial]. CMAJ 2003; 168(3):249.
5. National Institute for Clinical Excellence (UK). Appraisal Consultation Document: Alzheimer's disease - donepezil, rivastigmine, galantamine and memantine (review). Available: www.nice.org.uk/page.aspx?o=245909 (accessed 2005 Apr 18).
6. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamin, and memantine for Alzheimer's Disease. Technology assessment report commissioned by the HTA program on behalf of The National Institute for Clinical Excellence. Available: www.nice.org.uk/pdf/Alz_assessment_err_text.pdf (accessed 2005 Apr 18).